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he effective treatment of hypertension is associ- T ated with decreased mortality and morbidity from 
many diseases including stroke, congestive heart 
failure, and renal failure.' In the vast majority 
of cases, the treatment of hypertension is most 
effectively accomplished in the outpatient setting. 
The main goal of treating hypertension is to lower 
the patient's blood pressure to the target level 
described by the Sixth Report of the Joint National 
Committee on the Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure (JNC VI1.2 In 
most patients, this target is 140/90 mm Hg but, in 
selected other populations, the goal may be as low 
as 125/75 mm Hg. For most patients, this will 
require one or more antihypertensive medications; 
selection of medications that a patient can tolerate 
for years is key in maintaining patient compliance. 
In a small number of circumstances, however, 
rapid and predictable lowering of blood pressure 
is needed. This must be accomplished in the hos- 
pital, most effectively with IV medications (Table), 
with close hemodynamic monitoring, and intense 
nursing care. These hypertensive emergencies 
include situations where there is evidence of ongo- 
ing target organ damage, such as intracerebral 
hemorrhage, acute aortic dissection, eclampsia, 
and pheochromocytoma crisis.3 Hypertension after 
coronary artery bypass surgery or during acute 
myocardial infarction also constitutes a hyperten- 
sive emergency, as do many other situations in 
which target organ damage is evident. 
Autoregulatory mechanisms provide some organ 
protection during extreme blood pressure elevation 
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and, for this reason, it is important to decrease 
blood pressure by no more than 25% or to a level 
of 160/110 mm Hg, over a period of minutes to 
hours, depending on the specific clinical situation. 
If blood pressure is decreased more aggressively, 
target organ ischemia can result. Subsequent sodi- 
um and fluid retention may necessitate diuretic use 
later in the treatment of the hypertensive emer- 
gency to maintain blood pressure control.4 
There are many other situations that constitute 
hypertensive urgencies that, while concerning, do 
not require immediate intervention as in the case of 
hypertensive emergencies. These situations require 
prompt lowering of blood pressure, usually within 24 
hours with the use of oral agents. Some examples of 
hypertensive urgencies are accelerated hyperten- 
sion (a blood pressure of 250/150 mm Hg, for exam- 
ple, in an asymptomatic person with no evidence 
of target organ damage can usually be treated as 
an urgency rather than an emergency), rebound 
hypertension after drug withdrawal, postoperative 
hypertension, and acute glomerulonephritis.5 
DRUG THERAPY FOR 
HYPERTENSIVE EMERGENCIES 
Once the diagnosis of hypertensive emergency has 
been made, the most commonly used IV drug for 
treatment is sodium nitroprusside. This drug has a 
nearly immediate onset of action and a short half 
life. It acts by causing relaxation of vascular smooth 
muscle, resulting in dilatation of peripheral arteries 
and veins. For these reasons, the patient's blood 
pressure can be precisely titrated to the desired 
level.6 Administration requires an IV infusion pump 
and an arterial line for continuous measurement of 
blood pressure. The usual dose is 0.25-1 0 p g  per 
kg per minute, with the maximal dose to be used for 
only very short periods of time (<lo minutes). At 
rates of infusion >2 p g  per kg per minute, cyanide 
is generated faster than most patients can eliminate 
it. This production is initially buffered by serum 
methemoglobin which is normally present in the 
body. However, the system can be exhausted by the 
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1 TABLE. IV MEDICATIONS FOR HYPERTENSIVE EMERGENCIES I I DRUG USUAL 
DOSAGE 
ADVANTAGES CONCERNS 
Sodium Nitroprusside 0.25-1 0 ug/kg/rnin 
Maximal dose for up 
to 10 minutes 
Labetalol 020 mg IV slow 
injection, with 
subsequent increasing 
doses of 40 mg and 80 mg 
to a total of 300 mg 
Alternatively, 2 rng/min 
continuous infusion 
Nearly immediate 
onset of action 
Short half life 
Enables precise titration 
to desired blood 
pressure level 
conversion to oral form 
cyanide or thiocyanate 
monitoring or toxicity 
Potential for easy 
No concern for 
Easy to administer 
Cyanide toxicity 
OThiocyanate Toxicity 
*Requires IV infusion 
pump and arterial line 
*Can cause 
hypotension 




control cannot be 
precisely titrated 
Fenoldopam 0.03-1.6 ug/kg/min No concern for *Requires IV infusion 
cyanide or thiocyanate 
monitoring or toxicity arterial line 
Can be used in 
patients with renal 
insufficiency or 
potential of renal 
dysfunction 
(immunosuppressed, 
diabetics, or after 
iodinated contrast agents) 
and may require 
*Expensive 
cyanide production from about 500 pg per kg of 
nitroprusside, the amount administered in 50 min- 
utes at a rate of 10 p,g per kg per minute.7 For this 
reason, therapy with nitroprusside at the maximum 
dose for >10 minutes is not recommended. Therapy 
with nitroprusside carries the risk of cyanide toxicity 
which can result in venous hyperoxemia, acidosis, 
mental status changes, and death. At some centers, 
sodium nitroprusside is administered concomitantly 
with sodium thiosulfate, minimizing the possibility of 
cyanide toxicity by providing sufficient substrate to 
aid the conversion of cyanide to thiocyanate. Thio- 
cyanate is excreted by the kidneys, is mildly neuro- 
toxic, and can cause confusion at high levels. 
Thiocyanate levels of >60 mg/L are mildly neurotox- 
ic, and can become life threatening at levels of about 
200 mg/L. Thiocyanate levels can be determined in 
most hospital laboratories within a reasonable time 
period and should be monitored in patients on nitro- 
prusside therapy, particularly for extended periods of 
time. Most importantly, therapy with nitroprusside 
should be as brief as possible, with oral antihyper- 
tensive agents started as soon as is practical-even 
shortly after the start of nitroprusside therapy. 
In patients with renal insufficiency, IV 
fenoldopam mesylate can provide an alternative to 
nitroprusside, but without the threat of cyanide and 
thiocyanate toxicity. This drug, given at 0.03-1.6 
Fall 1999 
pg/kg/min, also permits tight titration to the desired 
blood pressure level. Studies have been done 
demonstrating the safety of administration without 
invasive monitoring, but the clinician may choose to 
use invasive monitoring since fenoldopam has a 
similar ability to effects rapid changes in blood 
pressure. Although much more expensive than 
nitroprusside, fenoldopam provides a good option 
in patients with renal dysfunction, or even in 
patients with threatened renal dysfunction, such as 
diabetic patients who have recently received an 
iodinated contrast agent. Transplant patients 
receiving nephrotoxic immunosuppression, such as 
cyclosporine or tacrolimus, may also be candidates 
for therapy with fenoldopam. 
IV labetalol provides another effective approach in 
treating the patient with a hypertensive emergency. 
This drug is a selective a,-adrenergic blocking 
agent, as well as a nonselective P-blocker.9 Labetalol 
is administered to the supine patient by slow IV injec- 
tion, usually of 20 mg, over 2 minutes with increasing 
does of 40 mg and 80 mg at 10 minute intervals until 
the blood pressure goal has been reached, or until a 
total of 300 mg of labetalol has been administered. 
Alternatively, a continuous IV infusion of labetalol at 2 
mg/min can be started, with subsequent adjustment. 
As with all IV antihypertensive agents, close patient 
monitoring is necessary, as hypotension and heart 
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block can occur. As with nitroprusside, oral antihy- 
pertensive therapy with labetalol or with other agents 
should be started as soon as possible. While blood 
pressure management with IV labetalol cannot be 
conducted as precisely as with nitroprusside, such 
precision is not always necessary and may be out- 
weighed by its several potential advantages: 1) con- 
cern and monitoring for cyanide and thiocyanate 
toxicity are not needed; 2) an oral form is available for 
easy conversion and long term use; and importantly; 
3) the drug comes in a vial that can be stored at room 
temperature and is available for immediate adminis- 
tration. Unlike nitroprusside, for which administration 
can be delayed by the acts of finding an infusion 
pump, preparation and delivery of the drug from 
pharmacy, and placement of an arterial monitoring 
line, therapy with IV labetalol can be initiated imme- 
diately following the diagnosis of a hypertensive 
ernergency. 
Another antihypertensive agent that can be used 
during hypertensive emergencies is enalaprilat. This 
IV ACE inhibitor causes a rapid decrease in blood 
pressure and may be of particular use in patients 
with stroke, as it may have a beneficial effect on 
cerebral vascular autoregulation during hyperten- 
sion.10 IV P-blockade can be accomplished with 
metoprolol or esmolol and injectable hydralazine, 
diltiazem, and verapamil are also useful. In the very 
rare pheochromocytoma crisis, phentolamine is the 
drug of choice. 
One of the most important goals in treating the 
patient with a hypertensive emergency is prompt 
institution of oral antihypertensive therapy, which 
should normally include a diuretic. This action will 
minimize the chance of IV drug related complica- 
tions, minimize the need for invasive monitoring, 
and minimize the patient’s hospital stay-particular- 
ly in the costly ICU. During this time, the patient 
should be educated regarding the importance of 
proper blood pressure control and, toward dis- 
charge, significant effort should be made to stream- 
line the patient’s antihypertensive regimen in order 
to enhance outpatient compliance. 
HYPERTENSIVE URGENCIES 
Hypertensive urgencies can usually be treated in 
the outpatient setting. Numerous drugs, including 
captopril, clonidine, labetalol, prazosin, and other 
agents, can be given orally and can cause reduc- 
tion of blood pressure in a matter of hours. The 
patient should generally be seen at follow up with- 
in 24-48 hours from initiation of therapy. Subse- 
quent treatment should be tailored to the long term 
treaiment of the patient’s hypertension, with partic- 
ular attention given to the selection of an antihyper- 
tensive regimen that will be well tolerated by the 
patient, affordable, and effective in reaching the tar- 
get goals as outlined in JNC VI. 
SHORT ACTING NlFEDlPlNE 
The widespread practice of administering immedi- 
ate release nifedipine, either orally or sublingually, 
during hypertensive urgencies and emergencies 
has resulted in numerous reports of adverse events. 
These are certainly related to the precipitous drop 
in blood pressure that this practice causes. These 
reports have prompted the FDA to recommend 
against the use of immediate acting nifedipine in 
the treatment of hypertensive urgencies and emer- 
gencies.11 Unfortunately, this practice continues in 
many settings, as the resulting sharp drop in blood 
pressure accomplishes a perceived short term goal 
of “getting the numbers down quickly.” Health care 
providers should discourage this use of nifedipine 
whenever possible as the risks far outweigh the 
benefit of this very temporary drop in blood pres- 
sure. If the situation is truly a hypertensive urgency 
or emergency, other agents, as described above, 
should be used. 
CONCLUSION 
Patients with severe hypertension need to be treat- 
ed in a variety of ways depending upon their pre- 
sentation. Asymptomatic patients with no evidence 
of ongoing target organ damage can simply be 
started on long term antihypertensive therapy and, 
if indicated, be evaluated for a secondary cause of 
hypertension. Patients with hypertensive emergen- 
cies require prompt therapy for their elevated blood 
pressure in a hospital setting. Patients with hyper- 
tensive urgencies can usually be treated as outpa- 
tients, providing rapid follow up is available. The 
long term goal of selecting a tolerable antihyperten- 
sive regimen for the patient’s chronic use must be 
continuously considered and assessment of other 
cardiovascular risk factors, such as smoking, dia- 
betes, and lipids, should be made at the same time 
as the institution of antihypertensive therapy. 
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es. Finally, the Working Group will try to contribute 
to European nursing research by setting up an 
international research project in the field of cardiac 
nursing. 
In conclusion, the Working Group on Cardiovas- 
cular Nursing is a dynamic group of nurses within 
the European Society of Cardiology, trying to 
improve the care for cardiovascular patients by 
facilitating international education, research, and 
networking. We would like to invite European and 
American nurses to submit abstracts for the next 
conference, which will be held from August 26-30, 
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of a goal blood pressure may be the most signifi- 
cant move toward improving long term outcomes 
for the 60 million Americans who suffer hyperten- 
sion. The challenge is before us. 
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2000, in Amsterdam, The Netherlands. For more 
information on the Working Group on Cardiovascu- 
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conference in Amsterdam, or applications for Nurse 
Fellowship of the European Society of Cardiology, 
we gladly refer to the website of the ESC 
(http://www.escardio.org/). 
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